greeksoup/ stock research
Stock research / United States / JNJ / Insiders

Johnson & Johnson insider trading

In twelve months insiders at Johnson & Johnson bought $258K and sold $151M on the open market; none of the 28 sales was under a plan set in advance.

Bought on the open market$258K1 purchase
Sold on the open market$151M28 sales
Sales set in advanceNoneall 28 chosen by the insider
Pay taken in stockNone
New to this? How to read this page
  1. Insiders are the people who run the company: officers, directors and owners of 10% or more. They must report a trade on Form 4 within two business days.
  2. A purchase on the open market is the strongest sign: the insider spent their own money.
  3. A sale under a trading plan (Rule 10b5-1) says little: its dates were fixed months before. Sales outside a plan say more, but insiders sell for many reasons, such as taxes or a house.
  4. Grants, option exercises and shares held back for tax are left out.
  5. What is a Form 4? · Form 4 codes

What kind of trades

1 purchase worth $258K against 28 sales worth $151M; no sale was under a plan set in advance.

Purchasebought with their own money
Pay in stock, own choiceowed cash, chose shares
Sale outside a planthe insider picked the day
Sale under a plandates fixed months before
Says littlecompany plans, board pay, cash units
Bought
1 open market
Sold
28 outside a plan

Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.

Insider trades on the share price

last twelve months

17 marks over twelve months, each in its grade: solid for the stronger signs, hollow or grey for the ones that say little.

PurchasePay in stock, own choiceSale outside a planSale under a planSays little

The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.

Trades worth a closer look

A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.

Who traded

dollars, twelve months

11 insiders traded. The most: Duato Joaquin, sale outside a plan $66.8M.

One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.

How it compares

every company on the site

Open-market sales, twelve months

Open-market purchases, twelve months

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every Form 4 line

    Purchase: bought on the open market with their own moneyTook pay in stock, own choice: owed cash, chose shares instead; a softer signSale: sold on the open market, not under a plan set in advanceSale, trading plan: under a Rule 10b5-1 plan set up months before, so the date was fixed in advanceGrey lines: plan purchases, pay in stock taken by the whole board or under a company plan, and units paid in cash; they say little about the insider's own view
    TradedInsiderRoleTypeSharesPriceValueFiling
    2 September 2026Schmid TimothyEVP, WW Chair, MedTechSaleafter a 23% rise over three months · at its one-year high · Form 144 notice 2 September 202611,070$274.74$3.0 millionForm 4
    2 September 2026Schmid TimothyEVP, WW Chair, MedTechSaleafter a 23% rise over three months · at its one-year high · Form 144 notice 2 September 202622,527$274.74$6.2 millionForm 4
    17 August 2026Taubert Jennifer LEVP, WWC. Innovative MedicineSaleafter a 15% rise over three months · at its one-year high · Form 144 notice 17 August 202615,000$263.36$4.0 millionForm 4
    13 August 2026Duato JoaquinCEO and Chairman of the BoardSaleafter a 14% rise over three months · at its one-year high · Form 144 notice 13 August 202620,976$262.00$5.5 millionForm 4
    13 August 2026Duato JoaquinCEO and Chairman of the BoardSaleafter a 14% rise over three months · at its one-year high · Form 144 notice 13 August 2026102,315$261.00$26.7 millionForm 4
    6 August 2026Forminard ElizabethEVP, Chief Legal OfficerSaleafter a 15% rise over three months · 4% below its one-year high · Form 144 notice 6 August 20269,344$257.75$2.4 millionForm 4
    6 August 2026Forminard ElizabethEVP, Chief Legal OfficerSaleafter a 15% rise over three months · 4% below its one-year high · Form 144 notice 6 August 20266,574$255.93$1.7 millionForm 4
    5 August 2026Duato JoaquinCEO and Chairman of the BoardSaleafter a 15% rise over three months · 4% below its one-year high · Form 144 notice 5 August 202641,957$258.06$10.8 millionForm 4
    5 August 2026Duato JoaquinCEO and Chairman of the BoardSaleafter a 15% rise over three months · 4% below its one-year high · Form 144 notice 5 August 20266,523$258.74$1.7 millionForm 4
    20 July 2026Broadhurst VanessaEVP, Global Corp AffairsSaleafter a 8% rise over three months · 7% below its one-year high · Form 144 notice 20 July 202623,054$251.27$5.8 millionForm 4
    11 June 2026Wengel Kathryn EEVP, Chief TO and Risk OfficerSaleafter a 2% fall over three months · 4% below its one-year high · Form 144 notice 11 June 202610,000$241.15$2.4 millionForm 4
    27 February 2026Decker Robert JVP Corporate ControllerSaleafter a 20% rise over three months · at its one-year high · Form 144 notice 27 February 20264,075$247.87$1.0 millionForm 4
    20 February 2026Schmid TimothyEVP, WW Chair, MedTechSaleafter a 19% rise over three months · at its one-year high · Form 144 notice 20 February 20261,322$245.66$324,763Form 4
    18 February 2026Schmid TimothyEVP, WW Chair, MedTechSaleafter a 21% rise over three months · at its one-year high · Form 144 notice 18 February 202613,625$244.20$3.3 millionForm 4
    18 February 2026Schmid TimothyEVP, WW Chair, MedTechSaleafter a 21% rise over three months · at its one-year high · Form 144 notice 18 February 20268,998$244.53$2.2 millionForm 4
    17 February 2026Swanson James D.EVP, CIOSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202620,521$242.70$5.0 millionForm 4
    17 February 2026Wolk Joseph JExec VP, CFOSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202619,241$242.99$4.7 millionForm 4
    17 February 2026Wolk Joseph JExec VP, CFOSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202612,066$242.87$2.9 millionForm 4
    17 February 2026Wolk Joseph JExec VP, CFOSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202633,386$242.75$8.1 millionForm 4
    17 February 2026Wolk Joseph JExec VP, CFOSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202624,961$242.68$6.1 millionForm 4
    17 February 2026Reed John CEVP, Innovative Medicine, R&DSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202621,721$243.00$5.3 millionForm 4
    17 February 2026Reed John CEVP, Innovative Medicine, R&DSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 202629,927$243.00$7.3 millionForm 4
    17 February 2026Reed John CEVP, Innovative Medicine, R&DSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 20262,283$243.00$554,769Form 4
    17 February 2026Broadhurst VanessaEVP, Global Corp AffairsSaleafter a 22% rise over three months · at its one-year high · Form 144 notice 17 February 20266,197$243.39$1.5 millionForm 4
    13 February 2026Swanson James D.EVP, CIOSaleafter a 24% rise over three months · at its one-year high · Form 144 notice 13 February 202619,368$243.76$4.7 millionForm 4
    13 February 2026Swanson James D.EVP, CIOSaleafter a 24% rise over three months · at its one-year high · Form 144 notice 13 February 202622,191$243.71$5.4 millionForm 4
    26 January 2026Duato Joaquin, by spouseCEO and Chairman of the BoardSaleafter a 16% rise over three months · at its one-year high · Form 144 notice 26 January 202651,218$220.99$11.3 millionForm 4
    26 January 2026Duato Joaquin, by spouseCEO and Chairman of the BoardSaleafter a 16% rise over three months · at its one-year high · Form 144 notice 26 January 202648,782$221.48$10.8 millionForm 4
    26 November 2025Morikis John GDirectorPurchaseafter a 17% rise over three months · at its one-year high1,250$206.15$257,688Form 4
    A filing with several lines appears once per line.
    Read morePay taken in stock by the insider's own choice has the filing's footnote, word for word, in the note under it; for the others, hold the pointer on the type. An award filed at no price shows n/a.